XTL BIopharmaceuticals Limited Company Profile - May 01, 2011 by WrightReports

VIEWS: 10 PAGES: 10

More Info
									Company Fundamentals\Company Profile

   A Wright Investors' Service Research Report:

   XTL BIopharmaceuticals Limited
                                                                                       440 Wheelers Farms Road
                                                                                       Milford, CT 06461 U.S.A.


  COMPANY PROFILE
  Figures in Israel Shekels

                                  Wright Quality Rating:LCNN                             Key Data

   XTL BIopharmaceuticals Limited. The Group's principal activity is the acquisition,    Ticker:
   development and commercialization of therapeutics for the treatment of neurophatic    XTLB
   pain and, Hepatitis C. The Company is a development stage biotechnology company.
   It does not yet have any product sales and expects to consume cash until products     2008 Sales:
   are commercialised. The Company's shares are traded on the London, New York and
                                                                                         21,166,655
   Tel Aviv Stock Exchange.
                         Stock Chart                                  Officers
                                                                                         Major Industry:
                                                                     Chairman
                                                                                         Drugs, Cosmetics & Health
                                                                     Amit Yonay
                                                                                         Care
                                                               Chief Executive Officer
                                                                     Ron Bentsur         Sub Industry:
                                                                                         Ethical Drug Manufacturers
                                                                  Finance Director
                                                                     Bill Kessler        Country:
                                                                                         Israel

                                                                                         Currency:
                                                                                         Israel Shekels

                                                                                         Fiscal Year Ends:
                                                                                         December

                                                                                         Employees
                                                                                         8
               Stock Price (4/21/2011): 0.64
                 Recent stock performance                                                Exchanges:
                    1 Week        9.8%                                                   OTH
                    4 Weeks      26.4%
                    13 Weeks    -10.9%                                                   Share Type:
                    52 Weeks    123.5%
                                                                                         Ordinary
                       Earnings / Dividends (as of 12/31/2010)
                                              Earnings            Dividends               Market Capitalization:
   Most Recent Qtr                                      -0.01                        0.00 122,119,907
   Last 12 Months                                       -0.04            
								
To top